Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

TB transmission and prevention news

Show

From To
Tshepiso study: Preventive TB therapy not associated with poor pregnancy outcomes

Initiating isoniazid preventive therapy for tuberculosis during pregnancy is not associated with a higher rate of poor maternal or infant outcomes, according to observational results from the Tshepiso study presented at CROI.

Published
12 March 2019
From
Healio
Co-administration of dolutegravir-based treatment and short course of rifapentine/isoniazid (3HP) well tolerated in people living with HIV

Co-administration of dolutegravir-based antiretroviral therapy and short course (12 weeks) of rifapentine/isoniazid (3HP) for people living with HIV needing preventative treatment for latent tuberculosis (TB) infection was well

Published
12 March 2019
By
Carole Leach-Lemens
TB Preventive Therapy Safe in Pregnant Women

Pregnant women who are infected with HIV and are at risk of tuberculosis co-infection can undergo isoniazid prevention therapy without causing harm to themselves or their babies, researchers suggested here.

Published
08 March 2019
From
MedPage Today
49th Union World Conference on Lung Health: Integrating HIV treatment and TB preventative therapy greatly improves IPT adherence

When tuberculosis preventive therapy is delivered with HIV treatment services and patients get a choice in where they access treatment, completion of tuberculosis preventive therapy rises, helping to ensure people living with HIV stay healthy, researchers said here. This model of prevention should be scaled up in TB-HIV high burden settings, researchers said.

Published
05 November 2018
From
Science Speaks
49th Union World Conference on Lung Health: First promising TB vaccine candidate in 100 years needs more resources, researchers say

It's taken 100 years to see any progress in the development of a vaccine to prevent tuberculosis, a disease that kills 4,000 every day, Lucica Ditiu, executive director of the Stop TB Partnership said here. Even now, it remains uncertain that a new vaccine will see the light of day, she said, as more funding has yet to be secured for larger-scale trials to confirm the promising results of the M72 vaccine candidate.

Published
29 October 2018
From
Science Speaks
TB vaccine halves risk of disease in people with latent TB

A vaccine against tuberculosis (TB) reduced the risk of developing active TB in HIV-negative people with latent TB infection by 54% in a large phase 2b study

Published
10 October 2018
By
Keith Alcorn
One in five exposed to TB during HIV clinic visits, Malawi study finds

As many as one in five people attending an HIV clinic in Malawi had prolonged exposure to another patient with potentially infectious tuberculosis (TB) during the

Published
01 October 2018
By
Keith Alcorn
GSK candidate vaccine helps prevent active pulmonary tuberculosis in HIV negative adults in phase II study

Today, GSK and Aeras reported that GSK’s M72/AS01E[1] candidate vaccine significantly reduced the incidence of pulmonary tuberculosis disease in HIV-negative adults with latent tuberculosis infection[2] in an ongoing phase IIb clinical trial testing. These primary results published in the New England Journal of Medicine after two years of trial demonstrate an overall vaccine efficacy of 54%, with varied response rates observed in different demographic sub-groups.

Published
26 September 2018
From
Aeras
TB symptom screen less likely to detect active TB in people taking HIV treatment

The four-symptom screen for active tuberculosis (TB) that is recommended for all people living with HIV in lower-income settings is less likely to detect active TB in

Published
14 September 2018
By
Keith Alcorn
New TB cases occur rapidly among close contacts of people with pulmonary TB

The close contacts of people with active pulmonary tuberculosis (TB) have high rates of the disease, according to US and Canadian research published in The

Published
12 June 2018
By
Michael Carter
← First12345...17Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.